ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i5.817ppharm-169Research ArticleВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕVACCINATIONРОТАВИРУСНАЯ ИНФЕКЦИЯ. КАК ДЕЙСТВИТЕЛЬНО ЗАЩИТИТЬ ДЕТЕЙ ОТ ТЯЖЕЛЫХ ГАСТРОЭНТЕРИТОВ?ROTAVIRUS INFECTION. HOW TO REALLY PROTECT CHILDREN FROM SEVERE GASTROENTERITIS?ГречухаТ. А.GrechukhaT. A.

кандидат медицинских наук, старший научный сотрудник, врач-иммунолог отделения вакцинопрофилактики детей с отклонениями в состоянии здоровья КДЦ «НЦЗД» РАМН

MD, senior research scientist, immunologist of the vaccinal prevention department for children with health deviations of the SCCH

Grechukha@nczd.ruГалицкаяМ. Г.GalitskayaM. G.ГайворонскаяА. Г.GayvoronskayaA. G.Намазова-БарановаЛ. С.Namazova-BaranovaL. S.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская Федерация Российский национальный исследовательский медицинский университет имени Н.И. Пирогова, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation First Sechenov Moscow State Medical University, Russian Federation Pirogov Russian National Medical Research University, Moscow, Russian FederationRussian Federation201301102013105Педиатрическая фармакология1417Copyright © Гречуха Т.А., Галицкая М.Г., Гайворонская А.Г., Намазова-Баранова Л.С., 20132013Гречуха Т.А., Галицкая М.Г., Гайворонская А.Г., Намазова-Баранова Л.С.Grechukha T.A., Galitskaya M.G., Gayvoronskaya A.G., Namazova-Baranova L.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/169

According to the statistics of the recent 5 years, the share of rotavirus gastroenterites is 44-47% of all acute intestinal infections in children under 5 years of age in the Russian Federation. Up to 5% of mortality rate in children under 5 years of age is connected with rotavirus gastroenteritis. Rotavirus gastroenteritis takes an especially severe course in children of 6-24 months of age. The only reliable method of preventing this infection is vaccination. The authors present information on the rotavirus strains dominant in Russia and abroad, efficacy and safety of immunization with a pentavalent vaccine and the recommended schemes of its administration. This vaccine is registered in the Russian Federation; it is to be first used in the nearest future.

ротавирусштаммыдети раннего возраставакцинопрофилактикаэффективностьrotavirusstrainsinfantsvaccinal preventionefficacyReferencesArvin A. M., Greenberg H. B. Virology. 2006; 344: 240–249.Arvin A. M., Greenberg H. B. Virology. 2006; 344: 240–249.Centers for disease control and Prevention. Morb Mortal Wkly Rep. 2006; 55 (RR-12): 1–13.Centers for disease control and Prevention. Morb Mortal Wkly Rep. 2006; 55 (RR-12): 1–13.Banyia K. et al. Vaccine. 2012; 30S: A122–A130.Banyia K. et al. Vaccine. 2012; 30S: A122–A130.Podkolzin A. T. et al. Hospital-Based Surveillance of Rotavirus and other Viral Agents of Diarrhea in Children and Adults inPodkolzin A. T. et al. Hospital-Based Surveillance of Rotavirus and other Viral Agents of Diarrhea in Children and Adults inRussia, 2005–2007. The Journal of Infectious Diseases. 2009; 200: S228–33.Russia, 2005–2007. The Journal of Infectious Diseases. 2009; 200: S228–33.Centers for disease control and Prevention. Morb Mortal Wkly Rep. 2009; 58 (RR-2): 1–25.Centers for disease control and Prevention. Morb Mortal Wkly Rep. 2009; 58 (RR-2): 1–25.Velazquez F. R. et al. N Engl J Med. 1996; 335: 1022–1028.Velazquez F. R. et al. N Engl J Med. 1996; 335: 1022–1028.Isla Ogilvie, Hanane Khoury, Antoine C., El Khoury et al. Burden of rotavirus gastroenteritis in the pediatric population in Central andIsla Ogilvie, Hanane Khoury, Antoine C., El Khoury et al. Burden of rotavirus gastroenteritis in the pediatric population in Central andEastern Europe. Human Vaccines. 2011 May; 7 (5): 523–533.Eastern Europe. Human Vaccines. 2011 May; 7 (5): 523–533.Weekly epidemiological record. 2008; 47: 421–425.Weekly epidemiological record. 2008; 47: 421–425.URL: http://www.rospotrebnadzor.ruURL: http://www.rospotrebnadzor.ruИммунопрофилактика-2011. 3-е изд. Под ред. В. К. Таточенко, Н. А. Озерецкого, А. М. Федорова. Изд.: ИПК «Контент-пресс». 2011.Иммунопрофилактика-2011. 3-е изд. Под ред. В. К. Таточенко, Н. А. Озерецкого, А. М. Федорова. Изд.: ИПК «Контент-пресс». 2011.URL: http://www.rotateq.comURL: http://www.rotateq.comGoveia M. G. et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J. 2007; 26: 1099–1104.Goveia M. G. et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J. 2007; 26: 1099–1104.The results of the 31-st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Milan, Italy. May 28 June 1. 2013.The results of the 31-st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Milan, Italy. May 28 June 1. 2013.Rotavirus vaccines. WHO position paper. 2013 Jan 5; 88: 49–64. URL: http://www.who.int/werRotavirus vaccines. WHO position paper. 2013 Jan 5; 88: 49–64. URL: http://www.who.int/werНамазова-Баранова Л. С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.Намазова-Баранова Л. С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.

The authors declare that there are no conflicts of interest present.